Target intelligence / Profile preview

Highly accelerated region 1B (non-protein coding RNA) (HAR1B)

Target
HAR1B
Molecular classification
Long non-coding RNA, LincRNA (long intergenic non-coding RNA)
01

Overview

Highly accelerated region 1B (HAR1B, also known as HAR1R) is a long non-coding RNA (lncRNA) located at 20q13.33 in the human genome. HAR1B is part of the human accelerated region 1 (HAR1) locus, which is notable for its rapid evolution in humans compared to other vertebrates, suggesting a role in human-specific traits, possibly neurodevelopment. HAR1B is expressed in the adult brain and, like its counterpart HAR1A, may have functions in neurogenesis, though details remain unclear. Recent studies have linked HAR1B expression to pazopanib sensitivity in sarcoma cell lines and tissues, where higher HAR1B levels are associated with better response to the drug, and knockdown of HAR1B leads to pazopanib resistance. The molecular function of HAR1B is not well understood, and it is not known to encode a protein. HAR1B is a relatively understudied lncRNA, but emerging evidence suggests it may have clinical relevance in oncology, particularly as a potential biomarker for drug response.

Other names
HAR1RNCRNA00065LINC00065human accelerated region 1 reversenon-protein coding RNA 65long intergenic non-protein coding RNA 65highly accelerated region 1B
02

Mechanism of action

Expression level of HAR1B correlates with pazopanib sensitivity in sarcoma cell lines; knockdown of HAR1B confers resistance to pazopanib, suggesting HAR1B may modulate cellular response to this drug, but exact molecular mechanism is unknown

03

Biological functions

Gene regulationpotential role in neurogenesis (suggested by association with HAR1A in Cajal-Retzius neurons)possible involvement in cellular response to pazopanibregulation of cell viability (in vitro knockdown experiments show altered response to pazopanib in sarcoma cells)
04

Disease associations

Cancer (sarcoma, hepatocellular carcinoma, possibly others—evidence for altered expression correlating with clinical outcomes in sarcoma and hepatocellular carcinoma)
05

Safety considerations

None specifically reported for HAR1Bgeneral concerns with long non-coding RNA-targeted therapies (e.g., off-target effects, delivery challenges, incomplete mechanistic understanding) may apply
06

Interacting drugs

Pazopanib
07

Biomarkers

HAR1B expression is higher in pazopanib-sensitive sarcoma cells and tissues and in responders to pazopanib treatment, suggesting potential as a predictive biomarker for pazopanib response in sarcoma

Beyond the preview

Go deeper on Highly accelerated region 1B (non-protein coding RNA) (HAR1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Highly accelerated region 1B (non-protein coding RNA) (HAR1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call